| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| Other Sizes |
| Targets |
Maleamic acid is a metabolite of maleic acid. It serves as a key intermediate in organic synthesis and is used as a model substrate for enzymatic assays in vitro.
|
|---|---|
| ln Vitro |
In vitro, (Z)-4-Amino-4-oxobut-2-enoic acid is used as a substrate in studies of maleate metabolism. It is also used as a standard in metabolomics to study metabolic pathways.
|
| ln Vivo |
In vivo, this compound is an endogenous metabolite involved in metabolic pathways. It is studied in the context of metabolic disorders.
|
| Enzyme Assay |
A non-cell assay uses purified enzymes (e.g., maleate isomerase) and (Z)-4-Amino-4-oxobut-2-enoic acid as a substrate. The reaction is monitored by UV absorbance or by LC-MS to detect product formation.
|
| Cell Assay |
For cell studies, the compound can be added to culture medium to study its effects on cellular metabolism. It is used as a standard in metabolomics studies in cell lines.
|
| Animal Protocol |
In animal studies, (Z)-4-Amino-4-oxobut-2-enoic acid is studied by analyzing its levels in urine and plasma, particularly in models of metabolic disorders.
|
| ADME/Pharmacokinetics |
(Z)-4-Amino-4-oxobut-2-enoic acid is an endogenous metabolite with rapid renal clearance. Its half-life in plasma is short (minutes).
|
| Toxicity/Toxicokinetics |
The compound is of low toxicity, as it is an endogenous metabolite. High doses may cause metabolic acidosis.
|
| Additional Infomation |
Maleamic acid is a dicarboxylic acid monoamide of maleamic acid. It is both a metabolite of Escherichia coli and a xenobiotic metabolite of bacteria. It is a dicarboxylic acid monoamide and an α,β-unsaturated monocarboxylic acid. Its function is related to maleic acid. It is the conjugate acid of maleamide. Maleamic acid has been reported to exist in Pogostemon cablin and Trypanosoma brucei, and relevant data are available for reference.
(Z)-4-Amino-4-oxobut-2-enoic acid is used as a research standard for metabolomics and as a substrate for enzymatic assays. It is also used as a building block in organic synthesis. |
| Molecular Formula |
C4H5NO3
|
|---|---|
| Molecular Weight |
115.09
|
| Exact Mass |
115.027
|
| CAS # |
557-24-4
|
| PubChem CID |
5280451
|
| Appearance |
White to off-white solid powder
|
| Density |
1.376g/cm3
|
| Boiling Point |
408.6ºC at 760mmHg
|
| Melting Point |
158-161 °C(lit.)
|
| Flash Point |
200.9ºC
|
| Index of Refraction |
1.528
|
| LogP |
-1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
8
|
| Complexity |
138
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(=C\C(=O)O)\C(=O)N
|
| InChi Key |
FSQQTNAZHBEJLS-UPHRSURJSA-N
|
| InChi Code |
InChI=1S/C4H5NO3/c5-3(6)1-2-4(7)8/h1-2H,(H2,5,6)(H,7,8)/b2-1-
|
| Chemical Name |
(Z)-4-amino-4-oxobut-2-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~868.89 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (18.07 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (18.07 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (18.07 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.6889 mL | 43.4443 mL | 86.8885 mL | |
| 5 mM | 1.7378 mL | 8.6889 mL | 17.3777 mL | |
| 10 mM | 0.8689 mL | 4.3444 mL | 8.6889 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
